drugset / Trial / NCT01189396

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

NCT01189396

Phase 2 Completed 27 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI)), and a Placebo DPI in escalating and cumulative-doses up to 1440 mcg, eight (8) times of the proposed clinical dose.

Timeline

Start
2010-07
Primary completion
2010-12
Completion
2011-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 90 ug Inhaled
Subject Salbutamol Unknown 180 ug Inhaled